Login to Your Account

Other News To Note

Monday, April 30, 2012
The International Myeloma Foundation, of North Hollywood, Calif., said a new drug application (NDA) has been submitted for pomalidomide, an immunomodulatory agent for multiple myeloma developed by Summit, N.J.-based Celgene Corp. The NDA is seeking use of the drug in patients who no longer respond to other therapies.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription